{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    14,
    18
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_05",
        "affectedSection": "Study Flowchart / Visit Schedule",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Provided study visit scheduling flexibility by allowing optional phone visits at specific weeks."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_05",
        "affectedSection": "Section 1.3.3 - Other/Exploratory Objectives",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added exploratory endpoint for non-severe hypoglycemic events in responders."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_05",
        "affectedSection": "Section 3.4.2 - Other Restrictions and Precautions",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated guidance on DKA assessments, insulin dose reductions, and ketone monitoring."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_05",
        "affectedSection": "Statistical Analysis Plan",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified primary efficacy endpoint analysis methods and multiplicity procedures."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_03",
        "affectedSection": "Section 3.3.1 - Inclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed requirement regarding HbA1c stability during lead-in phase."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_05",
        "reasonText": "Provide study visit scheduling flexibility for subjects during the 24-week treatment period.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_05",
        "reasonText": "Enhance safety monitoring and risk mitigation for Diabetic Ketoacidosis (DKA).",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_03",
        "reasonText": "Regulatory authority feedback from the European Medicines Agency (EMA).",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_05",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Week -1 Visit",
        "beforeText": "Central laboratory HbA1c [previous value not specified]",
        "afterText": "Central laboratory HbA1c â‰¤10.5%",
        "summary": "Revised the upper range of the Week -1 Visit HbA1c."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_05",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "3.4",
        "beforeText": "null",
        "afterText": "Reductions in insulin doses of more than 20% are not recommended regardless of glucose values.",
        "summary": "Added specific restriction on insulin dose reduction to mitigate DKA risk."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_05",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Statistical Methods",
        "beforeText": "Single-step Dunnett procedure",
        "afterText": "Dunnett and Tamhane step-up procedure",
        "summary": "Updated multiplicity adjustment procedure for improved power."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_05",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.3.3",
        "beforeText": "null",
        "afterText": "Tubal Ligation in this protocol is not considered surgical sterilization",
        "summary": "Clarified definition of surgical sterilization for women of childbearing potential."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_03",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "3.3.1",
        "beforeText": "Requirement that HbA1c may not drop more than 0.5% during the lead-in phase",
        "afterText": "null",
        "summary": "Removed HbA1c stability requirement based on EMA feedback."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 3,
      "changeCount": 5
    }
  }
}